89bio (ETNB) Q2 R&D Jumps 131%
89bio (NASDAQ:ETNB), a clinical-stage biotech focused on metabolic and liver diseases, released its second quarter 2025 results on August 7, 2025. The company posted GAAP earnings per share of $(0.71), missing the consensus estimate of $(0.50) and falling below $(0.48) in Q2 2024. There was no revenue, as expected for a development-stage company. Expenses (GAAP) increased sharply, especially in research and development, reflecting both the ramp-up of late-stage clinical programs and a significant one-time payment for commercial manufacturing infrastructure. Management judged the quarter as broadly in line with its strategic focus on advancing pegozafermin, its lead candidate, but highlighted that the company remains in a clinical stage with no commercial revenue yet.
Source: Analyst estimates for the quarter provided by FactSet.
89bio develops new medicines for metabolic and liver diseases. Its lead asset, pegozafermin, is a drug candidate designed to treat serious conditions like metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and severe hypertriglyceridemia (SHTG).
Source Fool.com
